Following disappointing Phase 2 results, Pegcetacoplan will no longer be used in ALS patients.

Published Date: 29 Jun 2023

Pegcetacoplan failed to achieve its primary end point, which was a 52-week change in Combined Assessment of Function and Survival rank scores relative to placebo, in a trial involving 250 adults with sporadic ALS.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

When Should Immunocompromised Individuals Receive a COVID Booster?

2.

Home Screening Appeals to Women Facing Healthcare Barriers

3.

Quality of Life Similar With Proton Beam Therapy vs IMRT for Prostate Cancer

4.

Prolonged Screen Time Linked to Sleep Issues in Preschoolers

5.

Precision Medicine in mHSPC: Integrating Novel Biomarkers, Imaging, and Emerging Targeted Agents


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot